|
|
|
|
Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: A single ... - UroToday |
UroToday
The renal cell carcinoma incidence among renal transplant recipients is approximately 0.5%; however, a significant increase in the number of RCC in renal grafts can be expected in the forthcoming years due to the increase in donor age and in renal
|
|
Astellas and Theravance Announce European Marketing Authorization for VIBATIV ... - MarketWatch (press release) |
MarketWatch (press release)
New onset or worsening renal impairment occurred in patients who received VIBATIV(R). Renal adverse events were more likely to occur in patients with baseline comorbidities known to predispose patients to kidney dysfunction and in patients who received
|
|
Novartis Galvus shows efficacy in type 2 diabetes trial - Pharmaceutical Business Review |
Pharmaceutical Business Review
Novartis' 24-week, double-blind, randomized, multi-center, parallel-group, placebo-controlled trial evaluating Galvus (vildagliptin) has demonstrated safety profile generally equals to placebo in type 2 diabetes and moderate or severe renal impairment ...
Galvus® (Vildagliptin) Achieves Significant Improvement In Type-2 Diabetes ... Medical News Today
Novartis Drug Galvus Shown to Be Well-Tolerated and Effective in Patients With
|
|
Can an ACE inhibitor reduce the risk of developing progressive renal disease? - Journal of the American Academy of Physician Assistants |
Journal of the American Academy of Physician Assistants
African American patients are reported to have a higher incidence of end-stage renal disease (ESRD) 1 with current research implicating potential genetic factors that lead to progressive disease 2 or underrecognition of early-stage chronic kidney
|
|
|
|
|
<< Start < Prev 691 692 693 694 695 696 697 698 699 700 Next > End >>
|
|
Page 700 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
